What Medtronic's FY2026 10-K says: 12 signals
Medtronic filed its latest 10-K with the SEC on Jun 18, 2026. It discusses acquisition completed, AI investment and compliance burden.
Public (MDT)Medical Equipment Manufacturing10,000+ employeesmedtronic.comLinkedIn
- Filed
- Jun 18, 2026
- Period
- FY2026
- Fiscal year end
- 04/24
- Filings
- 1
10-K · latest 9
What Medtronic's 10-K filings say
- SEC EDGAR
10-K · FY2026
Filed · Fiscal year ends 04/24 · 12 signals
Completed IPO of Diabetes business (MiniMed) in March 2026, driving major organizational separation.
The separation of the Diabetes business into a new public company creates massive operational complexity, requiring the disentanglement of IT systems, supply chains, and financial reporting.
$173M
Acquisition and divestiture-related items in FY2026, including charges related to the Diabetes business separation.
Anticipates $250M pre-tax net tariff impact in fiscal year 2027.
Medtronic is bracing for a $250M financial hit from tariffs in FY2027, creating significant pressure on its cost structure and margins, and driving a need for supply chain optimization and cost-reduction solutions.
$250M
Estimated pre-tax net tariff impact
Medtronic is actively investing in AI and data analytics to create new standards of care, tailor therapies, and reduce clinical workload with products like its AccuRhythm AI algorithms.
AIdata and analyticsautomation
Medtronic completed spinoff of its Diabetes Business into MiniMed Group in March 2026.
The separation of the Diabetes business into a new public company, MiniMed, represents a significant strategic shift for Medtronic to focus on its core portfolios.
Acquired CathWorks Ltd. in April 2026 to enhance its Coronary & Peripheral Vascular division.
The acquisition of CathWorks aims to strengthen Medtronic's position in diagnosing and treating coronary artery disease.
Facing ongoing costs to comply with new E.U. medical device regulations.
The company is incurring incremental costs for contractors and third-party services to comply with new E.U.
$52M
Incremental costs of complying with new E.U. medical device regulations in prior fiscal year (2025).
Company-wide strategic initiative to turn data, AI, and automation into actionable insights.
Medtronic's leadership has prioritized leveraging AI and data analytics to tailor therapies, enable remote monitoring, and create new standards of care.
AIdata and analyticsautomation
Medtronic is driving growth through a series of recent product launches and approvals in its key Cardiovascular portfolio, including systems approved in the U.S.
pulsed field ablationTAVR
The company explicitly flags the ongoing conflict in the Middle East as a potential source of global supply chain disruptions and higher costs for energy, fuel, and transportation.
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Medtronic with the Signal API
One POST /v1/companies/enrich call with medtronic.com returns Medtronic 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"medtronic.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Medtronic 10-K
When did Medtronic file its latest 10-K?
What does Medtronic's latest 10-K say about restructuring?
Where can I find Medtronic's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .